|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
2
|
Choi Y, Sateia HF, Peairs KS and Stewart
RW: Screening for colorectal cancer. Semin Oncol. 44:34–44. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ahmed FE: Development of novel diagnostic
and prognostic molecular markers for sporadic colon cancer. Expert
Rev Mol Diagn. 5:337–352. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
5
|
Kaestner KH: The FoxA factors in
organogenesis and differentiation. Curr Opin Genet Dev. 20:527–532.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernardo GM and Keri RA: FOXA1: A
transcription factor with parallel functions in development and
cancer. Biosci Rep. 32:113–130. 2012. View Article : Google Scholar
|
|
7
|
Augello MA, Hickey TE and Knudsen KE:
FOXA1: Master of steroid receptor function in cancer. EMBO J.
30:3885–3894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katoh M, Igarashi M, Fukuda H, Nakagama H
and Katoh M: Cancer genetics and genomics of human FOX family
genes. Cancer Lett. 328:198–206. 2013. View Article : Google Scholar
|
|
9
|
Zhang G, Zhao Y, Liu Y, Kao LP, Wang X,
Skerry B and Li Z: FOXA1 defines cancer cell specificity. Sci Adv.
2:e15014732016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shou J, Lai Y, Xu J and Huang J:
Prognostic value of FOXA1 in breast cancer: A systematic review and
meta-analysis. Breast. 27:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park S, Koh E, Koo JS, Kim SI, Park BW and
Kim KS: Lack of both androgen receptor and forkhead box A1 (FOXA1)
expression is a poor prognostic factor in estrogen
receptor-positive breast cancers. Oncotarget. 8:82940–82955. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abe Y, Ijichi N, Ikeda K, Kayano H,
Horie-Inoue K, Takeda S and Inoue S: Forkhead box transcription
factor, forkhead box A1, shows negative association with lymph node
status in endo-metrial cancer, and represses cell proliferation and
migration of endometrial cancer cells. Cancer Sci. 103:806–812.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamashita H, Amponsa VO, Warrick JI, Zheng
Z, Clark PE, Raman JD, Wu XR, Mendelsohn C and DeGraff DJ: On a FOX
hunt: Functions of FOX transcriptional regulators in bladder
cancer. Nat Rev Urol. 14:98–106. 2017. View Article : Google Scholar
|
|
14
|
Reddy OL, Cates JM, Gellert LL, Crist HS,
Yang Z, Yamashita H, Taylor JA III, Smith JA Jr, Chang SS, Cookson
MS, et al: Loss of FOXA1 drives sexually dimorphic changes in
urothelial differentiation and is an independent predictor of poor
prognosis in bladder cancer. Am J Pathol. 185:1385–1395. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gan HY, Li N, Zhang Q and Feng ZZ:
Silencing FOXA1 gene regulates liver cancer cell apoptosis and cell
proliferation. Eur Rev Med Pharmacol Sci. 22:397–404.
2018.PubMed/NCBI
|
|
16
|
He S, Zhang J, Zhang W, Chen F and Luo R:
FOXA1 inhibits hepatocellular carcinoma progression by suppressing
PIK3R1 expression in male patients. J Exp Clin Cancer Res.
36:1752017. View Article : Google Scholar
|
|
17
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Zhang S, Zhu L and Ma S: Role of
transcription factor FOXA1 in non-small cell lung cancer. Mol Med
Rep. 17:509–521. 2018.
|
|
19
|
Li M, Zhang W, Liu C, Shi Y, Tang W, Chen
S, Gu H, Yin J, Zhang Z and Jiang P: Forkhead box A1 (FOXA1)
tagging polymorphisms and esophageal cancer risk in a Chinese
population: A fine-mapping study. Biomarkers. 21:523–529. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsourlakis MC, Eleftheriadou A, Stender A,
Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S,
Hinsch A, et al: FOXA1 expression is a strong independent predictor
of early PSA recurrence in ERG negative prostate cancers treated by
radical prostatectomy. Carcinogenesis. 38:1180–1187. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takayama K and Inoue S: Transcriptional
network of androgen receptor in prostate cancer progression. Int J
Urol. 20:756–768. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nucera C, Eeckhoute J, Finn S, Carroll JS,
Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, et al:
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin
Cancer Res. 15:3680–3689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma W, Jiang J, Li M, Wang H, Zhang H, He
X, Huang L and Zhou Q: The clinical significance of forkhead box
protein A1 and its role in colorectal cancer. Mol Med Rep.
14:2625–2631. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: AJCC cancer staging manual. 6th
edition. Springer-Verlag; New York, NY: 2002, View Article : Google Scholar
|
|
25
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brábek J, Mierke CT, Rösel D, Veselý P and
Fabry B: The role of the tissue microenvironment in the regulation
of cancer cell motility and invasion. Cell Commun Signal. 8:222010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kiechle FL and Zhang X: Apoptosis:
Biochemical aspects and clinical implications. Clin Chim Acta.
326:27–45. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren H, Zhang P, Tang Y, Wu M and Zhang W:
Forkhead box protein A1 is a prognostic predictor and promotes
tumor growth of gastric cancer. Onco Targets Ther. 8:3029–3039.
2015.PubMed/NCBI
|
|
29
|
Villarino AV, Kanno Y, Ferdinand JR and
O’Shea JJ: Mechanisms of Jak/STAT signaling in immunity and
disease. J Immunol. 194:21–27. 2015. View Article : Google Scholar :
|
|
30
|
Abroun S, Saki N, Ahmadvand M, Asghari F,
Salari F and Rahim F: STATs: An old Story, yet mesmerizing. Cell J.
17:395–411. 2015.PubMed/NCBI
|
|
31
|
Zundler S and Neurath MF: Integrating
immunologic signaling networks: The JAK/STAT pathway in colitis and
colitis-associated cancer. Vaccines (Basel). 4:E52016. View Article : Google Scholar
|
|
32
|
Guanizo AC, Fernando CD, Garama DJ and
Gough DJ: STAT3: A multifaceted oncoprotein. Growth Factors.
36:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aigner P, Just V and Stoiber D: STAT3
isoforms: Alternative fates in cancer. Cytokine Jul. 18:2018(Epub
ahead of print). pii:S1043-4666(18)30300-4.2018. View Article : Google Scholar
|
|
34
|
Lai PS, Rosa DA, Magdy Ali A, Gómez-Biagi
RF, Ball DP, Shouksmith AE and Gunning PT: A STAT inhibitor patent
review: Progress since 2011. Expert Opin Ther Pat. 25:1397–1421.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun X and Kaufman PD: Ki-67: More than a
proliferation marker. Chromosoma. 127:175–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ragab HM, Samy N, Afify M, El Maksoud NA
and Shaaban HM: Assessment of Ki-67 as a potential biomarker in
patients with breast cancer. J Genet Eng Biotechnol. 16:479–484.
2018. View Article : Google Scholar
|
|
37
|
Hilska M, Collan YU, O Laine VJ, Kössi J,
Hirsimäki P, Laato M and Roberts PJ: The significance of tumor
markers for proliferation and apoptosis in predicting survival in
colorectal cancer. Dis Colon Rectum. 48:2197–2208. 2005. View Article : Google Scholar
|
